Biogen Seeks Darzalex Rivalry in China for Multiple Myeloma with Felzartamab Deal

Why It Matters

The deal gives Biogen a foothold in China’s rapidly expanding multiple myeloma market and leverages domestic production incentives, potentially reshaping the anti‑CD38 landscape. A successful launch could diversify treatment options and erode Darzalex’s near‑monopoly in a high‑value therapeutic segment.

Key Takeaways

• Biogen pays up to $850 M for exclusive China rights to felzartamab.
• Felzartamab offers 1.5‑hour infusion versus Darzalex’s 7‑hour IV.
• Domestic manufacturing aligns with China’s policy incentives for local drugs.
• Forecast projects 14.6% share of $458 M Chinese MM market by 2029.

Pulse Analysis

Biogen’s acquisition of exclusive rights to felzartamab marks a strategic push into China’s lucrative multiple myeloma (MM) arena. By taking over the pending biologics licence application and partnering with TJ Biopharma’s Hangzhou GMP plant, Biogen not only secures a domestic supply chain but also aligns with Beijing’s broader push for home‑grown pharmaceuticals. This arrangement reduces reliance on imports, shortens logistics, and may qualify the product for fiscal subsidies and fast‑track regulatory pathways, all of which can accelerate market entry and improve pricing leverage.

The competitive dynamics hinge on administration convenience and clinical performance. Darzalex (daratumumab) currently commands 87.5% of global anti‑CD38 use, driven by its proven efficacy but hampered by a seven‑hour intravenous infusion. Felzartamab’s 1.5‑hour infusion offers a clear patient‑centric advantage, yet Janssen’s subcutaneous Darzalex Faspro, under trial in China, could narrow the gap with a three‑to‑five‑minute injection suitable for home use. Consequently, Biogen must demonstrate comparable Phase III outcomes and articulate a compelling value proposition beyond infusion time to win prescriber confidence.

China’s policy environment further tilts the playing field. Government incentives—volume‑based procurement, tax relief, and regulatory acceleration—favor domestically produced biologics. GlobalData forecasts felzartamab capturing 14.6% of the $458 million Chinese MM market by 2029, translating to roughly $67 million in sales. If Biogen can leverage local manufacturing, secure favorable reimbursement, and deliver robust efficacy data, the partnership could disrupt Darzalex’s dominance and set a precedent for future foreign‑local collaborations in high‑growth therapeutic segments.